Skip to main content
OpenTrials

Clinical trial condition

Anti-Dyskinesia Agents

Explore clinical trials studying Anti-Dyskinesia Agents. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Anti-Dyskinesia Agents trial results

Completed

Open-label, Long-term Safety Extension Study of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491932

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
  • Novartis Investigative Site Milwaukee, Wisconsin, United States
  • Novartis Investigative Site Innsbruck, Austria
View all 32 locations
View Trial Details
Completed

Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

NCT01491529

Conditions
Anti-Dyskinesia Agents, Basal Ganglia Diseases, Brain Diseases, +11 more
Locations
  • Novartis Investigative Site Sunnyvale, California, United States
  • Novartis Investigative Site Englewood, Colorado, United States
  • Novartis Investigative Site Tampa, Florida, United States
  • Novartis Investigative Site Kansas City, Kansas, United States
View all 39 locations
View Trial Details

Related conditions